Identification of true dependencies in cancer is pivotal to the elucidation of novel therapeutic strategies to increase prospects for cancer patients. Unfortunately, in vivo identification of genetic dependencies has long relied on expensive and time-consuming breeding of genetically engineered animal models.
Introduction
Genome-scale viability-based negative selection screens using CRISPR/Cas9 have emerged as a powerful technique for identification of cancer cell vulnerabilities [1] [2] [3] . In vivo and smaller scale negative selection screens have also been described, employing CRISPR/Cas9 libraries transduced in cancer cell cultures subsequently transferred into sub-lethally irradiated mice 4 . However and ideally, genuine in vivo negative selection screens should take place in autochthonous tumors that are preferentially induced by genetic modification of clinically relevant cancer drivers 5 . While previously published work has hinted at the possibility of in vivo CRISPR/Cas9-based negative selection identification of genetic dependencies 6 , to our knowledge, the methodology and a proof-of-principle have not been previously reported. In negative-selection CRISPR screens, the feasibility of Cas9 to generate in-frame insertions-deletions (INDELs) has previously been considered a nuisance, as these in-frame mutations can encode protein with intact functions, allowing escape of imposed negative selection pressure and making downstream data interpretation challenging. It has indeed been demonstrated in these screens that targeting of gRNAs to functional protein domains substantially increases the potency of negative selection, as these in-frame mutations are structurally unlikely to be tolerated 7 . In direct contrast to the consensus that retention of in-frame variants in true genetic dependencies is unwanted and confounds data interpretation in a CRISPR screen, we show here how selection of in-frame functional variants following CRISPR/Cas9 editing can in fact be exploited as an identification tool for genetic cancer dependencies.
We label this methodology CRISPR/Cas9-mediated Negative-Selection Identification of genetic Dependencies (CRISPR-NSID). CRISPR-NSID employs multiplex CRISPR/Cas9 for identification of genetic dependencies, via concomitant CRISPR/Cas9-mediated editing of tumor suppressor genes and genes mediating putative genetic dependencies. When targeting a factual genetic dependency, the imposed Darwinian selection mechanisms will result in retention of a higher-than-expected frequency of in-frame mutations in developing tumors. We show how this phenomenon can be exploited to identify genetic dependencies via binomial probability statistics, integrating known a priori probabilities of in-frame editing occurring in absence of selection pressure.
We had previously shown that targeting the mutation cluster region (MCR) of the adenomatous polyposis coli (apc) gene by TALENs allowed accurate modeling of desmoid tumors/desmoid-type fibromatosis associated with the familial adenomatous polyposis (FAP) syndrome in Xenopus tropicalis (X. tropicalis) 8 . Clinically, desmoid tumors are associated with either activating mutations in the CTNNB1 gene, which encodes β-catenin, or with biallelic APC mutations and are a frequent cause of FAP patient morbidity 9 . Since there is no evidence-based consensus treatment for desmoid tumors, there is a large unmet clinical need for targeted therapeutic agents in this tumor entity 10 . Desmoid tumors are considered purely monoclonal and non-metastasizing tumors, as such we reasoned this tumor type to be uniquely positioned to employ CRISPR-NSID for identification of dependency factors. In fact, tumors can be easily sampled as monoclonal outgrowths in Xenopus cancer models favoring straightforward genetic analysis 11 . In this study, we use CRISPR-NSID to identify EZH2 and CREB3L1 as novel dependency factors for desmoid tumors. Furthermore, we demonstrate that chemical inhibition of EZH2 can generate a therapeutic response in established desmoid tumors in our apc CRISPR/Cas9-driven tumor model, thereby creating an incentive for future pre-clinical studies.
Results

apc tumor suppressor gene inactivation initiates desmoid tumorigenesis in Xenopus tropicalis
We previously demonstrated penetrant induction of desmoid tumors (DT) by tissue-restricted TALENsmediated genome engineering of apc in the anterior endoderm 8 . In the meanwhile, the advent of multiplex CRISPR/Cas9 for parallel gene inactivation pruned us to investigate whether DTs could similarly be induced by CRISPR/Cas9, in order to facilitate further downstream multiplexed gene inactivation studies 12 . We performed CRISPR/Cas9-mediated genome engineering of apc, in transgenic 8-cell embryos carrying a Wnt/β-catenin reporter construct 13 (Table S1a) . Mosaic mutant F0 animals, further called crispants, presented with fully penetrant (100%; n=10) multiple desmoid tumors demonstrating active Wnt signaling and relevant histopathological hallmarks ( Fig. S1a-c) . Finally, targeted amplicon sequencing of a DT revealed positive selection for biallelic CRISPR/Cas9-induced apc frame shifting INDEL mutations (Table S1b) . Interestingly, we also generated animals with a germline heterozygous one base pair deletion in the mutation cluster region (MCR) of the apc gene (apc MCR/+ ), which similarly developed DTs (Fig. S1d) resembling the clinical presentation of FAP patients.
Identifying potential desmoid tumor genetic dependencies by a gene expression signature and literature mining
To compile a list of possible genetic dependencies desmoid tumors, we re-analyzed previously published transcriptomics studies to identify genes that are consistently upregulated in desmoid tumors compared to other fibrotic lesions 14, 15 . We identified 251 genes that were over-expressed in DTs in two independent datasets. Gene Set Enrichment Analysis revealed the Wnt signaling network to be amongst the top enriched pathways (adjusted p < 0.001) and showed that transcription factors are the most overrepresented gene family in DTs (16/251 genes) (Table S2 ). According to the ARCHS4 database, CREB3L1 was the most significant transcription factor, expression of which highly correlated with expression levels of 58/251 genes that were upregulated in DTs (adjusted p = 1.34 x 10 -49
). We further mined the literature for genes previously shown to be associated with DT or previously associated with oncogenic processes. Additionally, we focused our efforts on genes for which the protein product was expected to be druggable in order to facilitate rapid clinical translation via drug repurposing approaches.
As such we compiled the following putative dependency factors for essentiality screening in apc biallelic (Table S3) .
CRISPR-NSID identifies ezh2 and creb3l1 as genetic dependencies for desmoid tumors
We devised a strategy to identify genetic dependencies for desmoid tumors (i.e. potential targets for therapy) by multiplex CRISPR/Cas9 genome editing. We assumed that, if a gene is essential for DT development, there will be selection pressure to prevent tumor outgrowth in the absence of this dependency factor. This implies that, upon simultaneous in vivo CRISPR/Cas9-mediated editing of apc and a true dependency gene, biallelic frameshift mutations in this dependency gene will never be observed when performing genomic analysis of DTs sampled from these crispant animals. We first validated putative dependency factor (PuDF) gRNAs for high-efficiency genome editing upon unilateral or bilateral injection in two-cell X. tropicalis embryos ( Evidently, we needed to verify that the incapability of recovering desmoid tumors carrying biallelic frameshift mutations in ezh2 S692 or creb3l1 L207 is not simply the consequence of under sampling, but rather reflects underlying negative selection mechanisms. In fact, it could be otherwise reasoned that not enough tumors were sampled to identify those carrying biallelic frameshift mutations, especially considering that we are dealing with mosaic edited animals. Therefore we devised a binomial statistics driven methodology using a priori probability of recovering biallelic frameshift mutations in a biallelic mutant DT and subjecting these expectations to real-life desmoid tumor sequencing data. For the frogs from the apc/ezh2 S692 and apc/creb3l1 L207 cohorts from which DTs were sampled, we also extracted DNA from the heart, an organ also receiving significant contribution from the injected dorsal-vegetal blastomeres, and performed genetic analysis of the ezh2 S692 and creb3l1 L207 loci. This provided us with an experimentally determined CRISPR/Cas9 INDEL scarring pattern for the employed gRNAs in each heart and allowed determination of the average frequency of frameshift mutations occurring across all hearts, in the absence of selection mechanisms. As such, we determine the average probability of frameshift editing for the ezh2 S692 and creb3l1 L207 gRNAs (pFrameshift). Obtaining this experimentally determined probability allows approximation of the probability of co-occurring biallelic frameshift mutations in a single desmoid tumor (pFrameshift²). As such we can calculate the binomial probability that for a sampled number of biallelic mutant tumors, we never sample a biallelic frameshift mutant tumor. Using this methodology, we calculated the average probability of ezh2 S692 and creb3l1 L207 frameshift mutations occurring in hearts and used these to calculate the probability of observing a biallelic frameshift mutation in a desmoid tumor (Table S5a-f). The binomial probability of never observing biallelic frameshift mutations in the sampled biallelic mutant desmoid tumors is smaller than the 5% chance cutoff for ezh2 S692 (p=0.033; n=4) ( Fig. 1b) and creb3l1 L207 (p=0.015; n=4) ( Table S5c , f). Hence, the chance of never observing ezh2 S692 or creb3l1 L207 biallelic frameshift mutations in four biallelic mutant desmoid tumors, given the a priori probability for frameshift editing events obtained from hearts, is 3.3% and 1.5%, respectively, and therefore binomially unlikely. This never occurs in practice so that each desmoid tumor, as a consequence of Darwinian negative selection mechanisms, retains at least one wild type or functional in-frame allele for ezh2 and creb3l1.
Interestingly, it was shown recently that double strand break repair by Non-Homologous End Joining upon template-free Cas9 editing is much less random than previously assumed and the INDEL pattern can be predicted by using the inDelphi bio-informatics tool 25 . biallelic frameshift mutations but instead recover a statistically significant higher-than-expected ratio of in-frame mutations, indicating a dependency of desmoid tumors on Ezh2 and Creb3l1 protein.
In-frame ezh2 mutations observed in desmoid tumors encode functional Ezh2 protein variants
Next, we sought to validate whether in-frame genetic variants, occurring upon ezh2 S692 gRNA editing, encode Ezh2 protein variants that retain expression and functionality, which is obligate if they are indeed genetic dependencies. We performed structural modeling revealing that the three deletion variants map within a loop region at the periphery of the EZH2 subunit (Fig. 2a) . Further, analysis of the structure of Anolis carolinensis EZH2 (acEZH2) within the PCR2 complex assembled from human EED, human SUZ12-VEFS, and AcEZH2 reveals that all three deletion variants would be expected to be well tolerated structurally 26 . Please note here the significant conservation of sequence identity between human EZH2, AcEZH2 and X. tropicalis Ezh2 (Fig. 2a) . Next, we performed expression studies introducing these EZH2
protein variants, as C-terminal Myc-tagged proteins, in Xenopus tropicalis embryos and HEK293T cells.
We included in all expression assays, as a positive control, an Ezh2(p.Y643F) gain-of-function variant, corresponding to human EZH2(p.Y641F) that has been shown to increase histone 3 lysine 27 trimethylation activity relative to wild-type Ezh2 27 . In the Xenopus embryo expression assay, all Ezh2 variant proteins could be readily detected, with the exception of the Ezh2(p.Lys658fs) variant that lacks the C-terminal Myc-tag ( Fig. 2b-top ). We performed CRISPR-NSID revealing negative selection on biallelic suz12 frameshift mutations using a priori experimental heart data (p=0.048; n=7) and InDelphi predictions (p<0.01; n=7) ( Table 2, Table S1d , S4, S5g-i, S6a). Taken
together, these experiments demonstrate that both ezh2 and suz12 are genetic dependencies during desmoid tumor development, with selection pressure specifically on the SET-domain of Ezh2, making a strong case for a dependency on functional PCR2 during desmoid tumorigenesis.
Simultaneous negative and positive selection mechanisms during desmoid tumorigenesis upon targeting both ezh2 and tp53.
As a final extension to our CRISPR-NSID model, we performed triple multiplex parallel genome engineering of apc, ezh2 V659 and tp53 (Table 2, Table S1d , S6c) 29 . Interestingly, all desmoid tumors (n=8) sampled in this cohort demonstrated biallelic tp53 editing, an event calculated as binomially unlikely (p<0.01) based on editing efficiencies of the tp53 gRNA (Table S6d ). This includes four tumors exhibiting tp53 biallelic frameshift mutations indicating complete loss of p53 protein. This is indicative of positive selection pressure for inactivating p53, in line with published work 30 . In contrast, once again none of these desmoid tumors presented with biallelic mutations in ezh2 (n=8). This experiment therefore also reveals that the necessity on retaining functional Ezh2 during desmoid tumor development, cannot be bypassed by inactivation of p53 31 .
EZH2 inhibition as therapeutic approach for desmoid tumors
To further validate the clinical relevance of our findings, we investigated whether, in line with literature 32 , desmoid tumors indeed retain PRC2 complex activity. First, we demonstrated in clinical human desmoid tumors nuclear EZH2 immunoreactivity (Fig. S3) . Interestingly, another desmoid tumor dependency factor identified in this study, CREB3L1, is also expressed in these clinical samples (Fig. S3) .
Furthermore, we observed profound H3K27me3 immunoreactivity in Xenopus desmoid tumors obtained from a cohort of apc CRISPR/Cas9 injected animals (Fig. S3) . We believe our data this far provide solid genetic evidence demonstrating a necessity for PRC2, and per extensions the histone methyltransferase activity of EZH2, during desmoid tumorigenesis. However, as most patients will present with established desmoid tumors, we intended to investigate the effects of chemical EZH2 inhibition (EZH2i) on established desmoid tumors occurring in apc crispants. For this we exposed desmoid-tumor-bearing apc crispants to either EZH2i, via 10µM tazemetostat (EZP-6438), or mock treatment (Fig. 3A) . By immunoblotting we demonstrate a reduction of H3K27me3 in the liver of drug-exposed animals compared to mock-treated animals indicative of tazemetostat bioabsorption and effectivity in Xenopus (Fig. 3B) . Examination of tumor growth revealed reduction or stasis in desmoid tumor size in the treatment arm, in contrast to sustained tumor growth in the control arm (p < 0.05) (Fig. 3C-D) (Table   S6d ). We performed histopathological analysis of H&E-stained sections and staining for markers of proliferation and apoptosis, but could not observe immediate differences between tumors of the treatment and the control arm (data not shown). However, it should be pointed out that DTs are very slowly growing, thereby obscuring the identification of proliferation and cell death characteristics. Taken together, our CRISPR-NSID pipeline discovered a novel therapeutic strategy for treatment of FAPassociated desmoid tumors that we believe warrants further pre-clinical investigation. , these usually are dependent on a positive selection stimulus as negative selection pressure is much harder to ascertain. Namely, the absence of biallelic frameshift editing in tumors can always be attributed to the lack of sufficient sampling or insufficient genome editing, unless there are well-enforced a priori predictions of the expected genome editing outcomes and validation that sufficiently efficient genome editing indeed occurred. In this study we show that CRISPR-NSID is a rapid methodology for identification of novel genetic dependencies in an in vivo context. In fact, much akin to negative selection CRISPR screens in cell culture systems, both genetic dependency identification and concomitant elucidation of protein domains driving these dependencies are possible 7 . We show that the negative selection pressure during tumorigenesis on true genetic dependencies results in the recovery of specific in-frame variants encoding mutant proteins retaining expression and functionality.
Discussion
We expect CRISPR-NSID to be applicable across a wide range of cancers and to be further adaptable to other model systems where CRISPR/Cas9 multiplexing can be easily achieved, such as zebrafish or tumor organoid culture systems. Furthermore, this methodology could also be adaptable to target specific PuDFs, in a hypothesis driven setting, in established cancer mouse models. Namely, in these models PuDF CRISPR/Cas9 scarring patterns and selection for tumors retaining at least one functional in-frame mutant can be investigated. We further believe that the necessity to experimentally determine the CRISPR/Cas9 scarring patterns in absence of selection, in order to perform a CRISPR-NSID analysis could in exploratory setups be replaced by scarring prediction software tools such as inDelphi 25 . Namely, the advent of machine learning in scarring prediction software is expected to yield increasingly accurate predictions of scarring patterns under absence of selection pressure, which can be back correlated to experimental tumor data. As such, we expect the CRISPR-NSID methodology to be uniquely positioned for in vivo validation of genetic dependencies identified in negative selection CRISPR/Cas9 screens in cancer cell cultures or in vivo xenografts of the latter.
In synopsis, we generated a new and highly penetrant CRISPR/Cas9-mediated model for desmoid-type fibromatosis in Xenopus tropicalis. We subsequently employed this model for CRISPR-NSID, elucidating new genetic dependencies on EZH2 and CREB3L1 in desmoid tumors, for which the dependency on the functional PRC2 complex was further validated. Desmoid tumors are a major cause of morbidity in familial adenomatous polyposis patients 9 , and we show here for the first time that EZH2 inhibition, via a well-tolerated drug already in clinical trials (Tazemetostat -EPZ6438) 28 , could be a novel therapeutic treatment for recurrent desmoid tumors.
Material and Methods
Generating the apc MCR/+ line F0 apc mosaics generated by apc TALENs injection 8 were outcrossed with WT X. tropicalis, and offspring was genotyped to identify heterozygotes via heteroduplex mobility assay as described before 34 . One distinct band pattern on heteroduplex mobility analysis (HMA) 34 , was determined, by deep amplicon sequencing and BATCH-GE, to be indicative of a one base pair deletion in apc and these animals were grouped and further raised for analysis.
gRNA design and generation
apc gRNA was designed with the Doench, Hartenian algorithm 35 . . tp53 gRNA was generated as described before 29 .
In vitro transcription, purification and quality control of injection-ready gRNA was performed as described before (Table S7a) 11 .
DNA extraction and targeted deep sequencing
In order to analyze CRISPR/Cas9 genome editing efficiencies, tadpoles, tissue or tumors were incubated overnight at 55 °C in lysis buffer (50 mM Tris pH 8.8, 1 mM EDTA, 0.5% Tween-20, 200 μg/ml proteinase K). For assessing total genome editing efficiency for a specific injection setup we pooled nine stage 46 tadpoles before performing lysis. CRISPR/Cas9-target-site-containing amplicons were amplified by PCR with the primer pairs shown in Table S7b . Deep amplicon sequencing was performed with a validated pipe-line, INDEL frequency data and variant calling for all sequencing was performed with BATCH-GE bioinformatics analysis 37 .
Generation of X. tropicalis mosaic mutants by CRISPR/Cas9
Wild-type Xenopus tropicalis females and males were primed with 20U and 10U PREGNYL© human chorionic gonadotropine (hCG) (Merck), respectively. Natural matings were set-up 2 days later, after boosting the female and male with 150U and 100U of hCG, respectively. Embryos were injected with the concentrations of RNP and within the blastomeres described in Table S7c . For all experiments we used NLS-Cas9-NLS (VIB Protein Service Facility, UGent), generated as described before 11 . All experiments were approved by the Ethical Committee for Animal Experimentation from Ghent University, Faculty of Science and VIB-Site Ghent. All methods were carried out in accordance with the relevant guidelines set out by this committee.
Differential expression analysis
In order to identify genes that are consistently upregulated in desmoid tumor fibromatosis compared to other fibrotic lesions, we re-analyzed the data from two previously published studies. The first dataset was generated by gene expression microarrays from 8 desmoid tumors, 10 dermatofibrosarcoma protuberans and 13 solitary fibrous tumors tumors 14 . The second dataset comprised 7 desmoid tumors compared to 9 different types of fibrous lesions that were profiled by 3SEQ 15 . We performed multiclass differential expression analyses using SAM for microarray data and SAMseq for 3SEQ data. We identified 251 genes (Table S2 ) that were upregulated in desmoid tumros in both datasets with contrast ≥2 and false detection rate ≤ 0.01. We performed functional annotation of these 251 genes using Gene Set Enrichment Analysis (GSEA) (MSigDB, Molecular Signatures Database v6.2). Druggability was assessed via the DGIdb database 38 .
CRISPR-NSID
For assessment of PuDF gRNA efficiencies, each gRNA was injected together with Cas9 recombinant protein as pre-complexed ribonucleoproteins (RNP), either unilaterally or bilaterally, in two-cell X.
tropicalis embryos (Table S7c) . Genome editing efficiencies were determined as described above.
CRISPR-NSID was performed by multiplex CRISPR/Cas9, thus generating double crispants for both apc and respectively each of the eleven putative dependency factors (PuDF) under scrutiny. Genome editing efficiencies were determined as described above. Animals were further raised until post-metamorphosis.
Please note that, considering the fluctuating apc editing efficiencies across setups, direct comparison of DT incidence rates to delineate impact of PuDF knockout on desmoid tumorigenesis is impossible. For each animal developing one or multiple desmoid tumors, targeted PCR amplicon sequencing was performed for the apc and the respective PuDF within the desmoid tumors and, in most cases, the heart. Noteworthy, the heart is a tissue receiving significant contribution from the vegetal-dorsal lineage and as such will serve as a proxy to determine the probability of frameshift mutations occurring for a specific gRNA in absence of selection pressure. In practice, each isolated desmoid tumor will have a varying content of non-neoplastic cells, which will be edited at basal efficiencies similar to the vegetal-dorsal lineage of the animal 6 . In order to perform a CRISPR-NSID analysis, we require monoclonal tumors and as such all tumors which showed more than two frequent mutation read variants in the apc gene were excluded from further analysis. PuDF were excluded as genetic dependencies when they demonstrated biallelic frameshift mutations in desmoid tumors. When we could never sample desmoid tumors containing biallelic frameshift mutations in desmoid tumors, but instead sampled a larger than expected amount of in-frame mutations, we performed binomial analysis to determine whether the probability of observing this was less than the binomial probability cut-off of 5% (p < 0.05). Based on the a priori determined (a) probability of frameshift mutations across the average of hearts (experimental) or (b) as predicted by inDelphi software 25 (in silico -https://indelphi.giffordlab.mit.edu/), we calculated the probabilities of co-encountering two frameshift (biallelic) mutations in biallelic mutant tumors (p). We then used binomial distribution to model the number of biallelic frameshift mutations in a tumor sample of size n with probability of occurrence p. Then, the probability of getting exactly k biallelic frameshift mutations in n tumors can then be written as . As an example for ezh2
S692
, with n = 4 and p = 0.573, the occurrence of zero (k) biallelic frameshift mutations across the tumors is 0.0331.
Imaging, histology and immunohistochemistry
Pictures of desmoid-tumor bearing animals, including the active Wnt signaling within desmoid tumors by dEGFP fluorescence, were taken with a Carl Zeiss StereoLUMAR.V12 stereomicroscope. X. tropicalis desmoid tumor tissue samples were harvested from benzocaine euthanized animals, fixed overnight at 4 o C in 4% PFA, dehydrated and embedded in paraffin. Tissue sections were cut (5µm), stained and imaged as described before 11 . Clinical desmoid tumor samples were identified by D.C. and anonymized tissue sections were provided to perform immunofluorescence. Antigen retrieval was performed using a Hoechst-33342 and sections were imaged using a Leica TCS LSI zoom confocal microscope.
Expression of EZH2 protein variants
C-terminal Myc-epitope-tagged expression plasmid pCS2-MT-EZH2 was generated by cloning X. tropicalis 
In vivo EZH2 inhibition
DT-bearing apc crispants were generated as described before. Ninety day old animals were randomly Table 1 ). In the apc/ezh2 S692 cohort we obtained eight desmoid tumors, in which four exhibited biallelic mutations. None of these exhibited biallelic frameshift mutations. Using experimental data obtained from sequencing hearts in the apc/ezh2 S692 cohort, we predict the chance of biallelic frameshift mutation in any given desmoid tumor to be 57.34%, as such the probability of sampling zero biallelic frameshift mutations in four biallelic mutant tumors is 3.31% (p<0.05). Using the inDelphi tool, we predict the chance of biallelic frameshift mutation in any given desmoid tumor to be 51.84%, as such the probability of sampling zero biallelic frameshift mutations in four biallelic mutant tumors is 5.38%. Ezh2 protein variants we demonstrate that functionality as they increase H3K27me3 compared to the transfection control. Total H3 is shown as loading control. Immunoblots were cut and pasted (see white space in blots). Unaltered original scans of blots are shown in Supplementary Fig. S2 . Table S6D . *P < 0.05 Table 1 : CRISPR-NSID reveals dependency on functional Ezh2 and Creb3l1 during apc biallelic truncation driven desmoid tumorigenesis. Desmoid tumors are in all cases driven by biallelic out-offrame INDEL mutations in the apc gene (note that some DTs carry identical mutations on both alleles).
Furthermore, tumors carrying biallelic frameshift mutations in lox, adam12, mdk, hmmr, wisp1, nuak1, FAP-α, pclaf and pycr1 were sampled. Tumors carrying these biallelic frameshift mutations are highlighted in grey. In contrast, biallelic frameshift editing was never sampled for ezh2 or creb3l1, due to negative selection pressure on retention of functional Ezh2 and Crebl3l1 during desmoid tumorigenesis. are in all cases driven by biallelic mutations in the apc gene, of which some DTs carry identical mutations on both alleles. Biallelic frameshift editing never was never sampled in ezh2 or suz12, due to negative selection pressure leading to retention of functional Ezh2 and Suz12 during desmoid tumorigenesis.
Further, in a triple multiplex CRISPR/Cas9 editing contrast, tp53 biallelic mutations were readily Table 1 Table 2 Supplementary data Table S5 : CRISPR-NSID analysis. Data tables for the analysis of the CRISPR-NSID screening data in order to achieve binomial probabilities. 
